BeiGene HERIZON-GEA-01: Zanidatamab Plus Tislelizumab and Chemo Extends OS in HER2-Positive Gastroesophageal Adenocarcinoma, Difference Versus Zanidatamab Plus Chemo Not Significant

1. 20:00
   mp.weixin.qq.com

   HERIZON-GEA-01 Phase 3: Zanidatamab Plus Tislelizumab and Chemotherapy Lifts Median OS to 27.0 Months in First-Line HER2-Positive Advanced Gastric Cancer

   In the HERIZON-GEA-01 study, the zanidatamab plus tislelizumab plus chemotherapy arm achieved a median overall survival of 27.0 months in HER2-positive advanced gastroesophageal adenocarcinoma, with HR=0.65. The global multicenter phase 3 trial reported this second interim OS analysis after a median follow-up of 35.3 months; median OS was 19.6 months in the control arm and 22.9 months in the zanidatamab plus chemotherapy arm, HR=0.76, P=0.0088.

2. 09:40
   mp.weixin.qq.comPick

   BeiGene HERIZON-GEA-01: Zanidatamab Plus Tislelizumab and Chemo Extends OS in HER2-Positive Gastroesophageal Adenocarcinoma, Difference Versus Zanidatamab Plus Chemo Not Significant

   In the Phase 3 HERIZON-GEA-01 trial from BeiGene, zanidatamab combined with tislelizumab and chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma achieved a median overall survival of 27.0 months. The difference versus the zanidatamab plus chemotherapy group did not reach statistical significance.

Heat now 2·Peak in the comparable set 10 (Oct 24 20:00)·Change over 24h in the comparable set -50%·Participants now 1

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.